Abiopharma

🔍 Cheung Kong Yiu (Director)

Company: NewGenIvf Group Ltd (NIVF)

Report Date: 2026-05-28

Detailed Transactions and Holdings:

• Acquired 222,223 shares of Class A Ordinary Shares at $1.5 per share (Direct)
  Date: 2026-05-28 | Code: P | equity_swap_involved: 0 | shares_owned_after: 222,223.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 500,000 shares of Class A Ordinary Shares at $1.33 per share (Direct)
  Date: 2026-06-02 | Code: P | equity_swap_involved: 0 | shares_owned_after: 722,223.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 500,000 shares of Class A Ordinary Shares at $1.33 per share (Direct)
  Date: 2026-06-18 | Code: P | equity_swap_involved: 0 | shares_owned_after: 1,222,223.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 2,500,000 shares of Class A Ordinary Shares at $1.0 per share (Direct)
  Date: 2026-07-27 | Code: P | equity_swap_involved: 0 | shares_owned_after: 3,722,223.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: The Class A ordinary shares reported herein reflect Class A ordinary shares issued directly to the Reporting Person (as the "Seller") pursuant to the terms of certain share purchase agreements by and among the Issuer (as the "Buyer") and the Reporting Person. The share amounts reported in tranches (i) through (iii) have been adjusted to reflect a 1-for-3 reverse stock split: (i) 222,223 Class A ordinary shares (adjusted from 666,667 pre-split shares) issued under the Share Purchase Agreement dated May 28, 2026; (ii) 500,000 Class A ordinary shares (adjusted from 1,500,000 pre-split shares) issued under the Share Purchase Agreement dated June 2, 2026; (iii) 500,000 Class A ordinary shares (adjusted from 1,500,000 pre-split shares) issued under the Share Purchase Agreement dated June 18, 2026; and (iv) 2,500,000 Class A ordinary shares issued under the Share Purchase Agreement dated July 27, 2026.